Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease